Proteomic Analysis of the Cerebrospinal Fluid of Patients with Restless Legs Syndrome/Willis-Ekbom Disease

Overview

Journal Fluids Barriers CNS

Publisher Biomed Central

Date 2013 Jun 14

PMID 23758918

Citations 16

Authors

Stephanie M Patton

Yong Won Cho

Thomas W Clardy

Richard P Allen

Christopher J Earley

James R Connor

Affiliations

Soon will be listed here.

Abstract

Background: Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) is a sensorimotor disorder that causes patients to experience overwhelming and distressing sensations in the legs compelling the patient to move their legs to provide relief. The purpose of this study was to determine if biomarkers in the cerebrospinal fluid can distinguish RLS/WED patients from neurological controls.

Methods: We obtained CSF samples by lumbar puncture from 5 early-onset RLS/WED patients and 5 controls. We performed 2-dimensional difference in-gel electrophoresis (2D-DIGE). Proteins that were significantly altered were identified by Student's t-test. Protein spots that were differentially expressed (p ≤ 0.05, Av. Ratio ≥ 2.0) between RLS/WED and control CSF samples were identified using MALDI-TOF-MS. Statistical analyses of the validation immunoblot assays were performed using Student's t-test.

Results: In this discovery study we identified 6 candidate CSF protein markers for early-onset RLS/WED. Four proteins (Cystatin C, Lipocalin-type Prostaglandin D2 Synthase, Vitamin D binding Protein, and β-Hemoglobin) were increased and 2 proteins (Apolipoprotein A1 and α-1-acid Glycoprotein) were decreased in RLS/WED patients.

Conclusions: Our results reveal a protein profile in the RLS/WED CSF that is consistent with clinical findings of disruptive sleep, cardiovascular dysfunction and painful symptoms. Moreover, protein profiles are consistent with neuropathological findings of activation of hypoxia inducible factor (HIF) pathways and alterations in dopaminergic systems. These data indicate the CSF of RLS/WED patients may provide information relevant to biological basis for RLS/WED, treatment strategies and potential new treatment targets.

Citing Articles

Vitamin D binding protein in psychiatric and neurological disorders: Implications for diagnosis and treatment.

Li L, Han B, Kong Y, Zhang G, Zhang Z Genes Dis. 2024; 11(5):101309.

PMID: 38983447 PMC: 11231549. DOI: 10.1016/j.gendis.2024.101309.

Unveiling the pathophysiology of restless legs syndrome through transcriptome analysis.

Mogavero M, Salemi M, Lanza G, Rinaldi A, Marchese G, Ravo M iScience. 2024; 27(4):109568.

PMID: 38617564 PMC: 11015462. DOI: 10.1016/j.isci.2024.109568.

Proteomic insights into the pathophysiology of periodic limb movements and restless legs syndrome.

Cederberg K, Peris Sempere V, Lin L, Zhang J, Leary E, Moore H Sleep Health. 2023; 10(1S):S161-S169.

PMID: 37563071 PMC: 10850434. DOI: 10.1016/j.sleh.2023.06.008.

Vitamin D and Restless Legs Syndrome: A Review of Current Literature.

Cederberg K, Silvestri R, Walters A Tremor Other Hyperkinet Mov (N Y). 2023; 13:12.

PMID: 37034443 PMC: 10077981. DOI: 10.5334/tohm.741.

Searching for Novel Candidate Biomarkers of RLS in Blood by Proteomic Analysis.

Mondello S, Kobeissy F, Mechref Y, Zhao J, El Hayek S, Zibara K Nat Sci Sleep. 2021; 13:873-883.

PMID: 34234594 PMC: 8243594. DOI: 10.2147/NSS.S311801.

References

Chen G, Liu L, Xie S, Liu H, Liu Y, Li Y . High-density lipoprotein associated factors apoA-I and serum amyloid A in Chinese non-diabetic patients with coronary heart disease. Chin Med J (Engl). 2010; 123(6):658-63. View

Winkelman J, Finn L, Young T . Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med. 2006; 7(7):545-52. DOI: 10.1016/j.sleep.2006.01.004. View

Jordan W, Tumani H, Cohrs S, Eggert S, Rodenbeck A, Brunner E . Prostaglandin D synthase (beta-trace) in healthy human sleep. Sleep. 2004; 27(5):867-74. DOI: 10.1093/sleep/27.5.867. View

Patton S, Ponnuru P, Snyder A, Podskalny G, Connor J . Hypoxia-inducible factor pathway activation in restless legs syndrome patients. Eur J Neurol. 2011; 18(11):1329-35. DOI: 10.1111/j.1468-1331.2011.03397.x. View

Mannes A, Martin B, Yang H, Keller J, Lewin S, Gaiser R . Cystatin C as a cerebrospinal fluid biomarker for pain in humans. Pain. 2003; 102(3):251-256. DOI: 10.1016/S0304-3959(02)00403-7. View

Biagioli M, Pinto M, Cesselli D, Zaninello M, Lazarevic D, Roncaglia P . Unexpected expression of alpha- and beta-globin in mesencephalic dopaminergic neurons and glial cells. Proc Natl Acad Sci U S A. 2009; 106(36):15454-9. PMC: 2732704. DOI: 10.1073/pnas.0813216106. View

Weinstock L, Walters A, Paueksakon P . Restless legs syndrome--theoretical roles of inflammatory and immune mechanisms. Sleep Med Rev. 2012; 16(4):341-54. DOI: 10.1016/j.smrv.2011.09.003. View

Gomme P, Bertolini J . Therapeutic potential of vitamin D-binding protein. Trends Biotechnol. 2004; 22(7):340-5. DOI: 10.1016/j.tibtech.2004.05.001. View

Winter A, Berger K, Glynn R, Buring J, Gaziano J, Schurks M . Vascular risk factors, cardiovascular disease, and restless legs syndrome in men. Am J Med. 2013; 126(3):228-35, 235.e1-2. PMC: 3574273. DOI: 10.1016/j.amjmed.2012.06.039. View

10.

Winkelman J, Shahar E, Sharief I, Gottlieb D . Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology. 2008; 70(1):35-42. DOI: 10.1212/01.wnl.0000287072.93277.c9. View

11.

Ulfberg J, Nystrom B, Carter N, Edling C . Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord. 2001; 16(6):1159-63. DOI: 10.1002/mds.1209. View

12.

Liu X, Zeng B, Xu J, Zhu H, Xia Q . Proteomic analysis of the cerebrospinal fluid of patients with lumbar disk herniation. Proteomics. 2005; 6(3):1019-28. DOI: 10.1002/pmic.200500247. View

13.

Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg H, Buhmann C . Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res. 2001; 42(7):1143-51. View

14.

Schlesinger I, Erikh I, Avizohar O, Sprecher E, Yarnitsky D . Cardiovascular risk factors in restless legs syndrome. Mov Disord. 2009; 24(11):1587-92. DOI: 10.1002/mds.22486. View

15.

Barcelo A, De la Pena M, Barbe F, Pierola J, Bosch M, Agusti A . Prostaglandin D synthase (beta trace) levels in sleep apnea patients with and without sleepiness. Sleep Med. 2007; 8(5):509-11. DOI: 10.1016/j.sleep.2006.10.005. View

16.

Earley C, Connor J, Beard J, Clardy S, Allen R . Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. Sleep. 2005; 28(9):1069-75. DOI: 10.1093/sleep/28.9.1069. View

17.

Hening W, Allen R, Washburn M, Lesage S, Earley C . Validation of the Hopkins telephone diagnostic interview for restless legs syndrome. Sleep Med. 2007; 9(3):283-9. DOI: 10.1016/j.sleep.2007.04.021. View

18.

Jordan W, Hagedohm J, Wiltfang J, Laier-Groeneveld G, Tumani H, Rodenbeck A . Biochemical markers of cerebrovascular injury in sleep apnoea syndrome. Eur Respir J. 2002; 20(1):158-64. DOI: 10.1183/09031936.02.00862001. View

19.

dOnofrio F, Bussone G, Cologno D, Petretta V, Buzzi M, Tedeschi G . Restless legs syndrome and primary headaches: a clinical study. Neurol Sci. 2008; 29 Suppl 1:S169-72. DOI: 10.1007/s10072-008-0916-3. View

20.

Ohayon M, Roth T . Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res. 2002; 53(1):547-54. DOI: 10.1016/s0022-3999(02)00443-9. View